Global Cord Blood Corporation (CORBF)
OTCMKTS: CORBF · Delayed Price · USD
1.350
+0.100 (8.00%)
Jul 23, 2024, 12:00 PM EDT - Market closed
Global Cord Blood Revenue
In the fiscal year ending March 31, 2022, Global Cord Blood had annual revenue of $194.26M with 10.06% growth. Revenue in the quarter ending March 31, 2022 was $46.44M with 0.92% year-over-year growth.
Revenue (ttm)
$194.26M
Revenue Growth
+10.06%
P/S Ratio
0.93
Revenue / Employee
$161,613
Employees
1,202
Market Cap
180.79M
Revenue Chart
* The company reports in CNY currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2022 | 194.26M | 17.75M | 10.06% |
Mar 31, 2021 | 176.51M | 2.01M | 1.15% |
Mar 31, 2020 | 174.49M | 27.22M | 18.48% |
Mar 31, 2019 | 147.28M | -934.34K | -0.63% |
Mar 31, 2018 | 148.21M | 37.93M | 34.39% |
Mar 31, 2017 | 110.28M | 7.76M | 7.56% |
Mar 31, 2016 | 102.53M | -51.93K | -0.05% |
Mar 31, 2015 | 102.58M | 10.22M | 11.06% |
Mar 31, 2014 | 92.36M | 7.84M | 9.27% |
Mar 31, 2013 | 84.52M | 24.13M | 39.97% |
Mar 31, 2012 | 60.39M | 8.54M | 16.47% |
Mar 31, 2011 | 51.85M | 13.54M | 35.33% |
Mar 31, 2010 | 38.31M | 9.84M | 34.58% |
Mar 31, 2009 | 28.47M | -4.77M | -14.35% |
Mar 31, 2008 | 33.24M | 31.59M | 1,919.66% |
Mar 31, 2007 | 1.65M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
Novartis AG | 48.86B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
CORBF News
- 4 weeks ago - Global Cord Blood Corporation Investors With Losses Are Urged By The Schall Law Firm To Start Communication Be Mindful Of The Deadline In This Case - Accesswire
- 4 weeks ago - The Schall Law Firm Encourages Global Cord Blood Corporation Investors With Losses To Initiate Communication Be Conscious Of The Time Limit In This Situation - Accesswire
- 4 weeks ago - SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Global Cord Blood Corporation of Class Action Lawsuit and Upcoming Deadlines - CORBF - PRNewsWire
- 4 weeks ago - CO, CORBF DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important June 24 Deadline in Securities Class Action – CO, CORBF - GlobeNewsWire
- 4 weeks ago - CORBF Investors Have Opportunity to Join Global Cord Blood Corporation Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
- 4 weeks ago - Investors Who Have Incurred Losses In Global Cord Blood Corporation Are Encouraged By The Schall Law Firm To Reach Out Please Be Mindful Of The Deadline In This Matter - Accesswire
- 4 weeks ago - Investors Who Have Sustained Losses In Global Cord Blood Corporation Are Urged By The Schall Law Firm To Make Contact Please Be Aware Of The Deadline In This Case - Accesswire
- 4 weeks ago - SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Global Cord Blood Corporation of Class Action Lawsuit and Upcoming Deadlines – CORBF - GlobeNewsWire